Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201

多西紫杉醇 医学 中性粒细胞减少症 内科学 发热性中性粒细胞减少症 胃肠病学 白细胞减少症 化疗 危险系数 临床终点 紫杉醇 无进展生存期 肿瘤科 随机对照试验 外科 置信区间
作者
Sachiko Yamamoto,Hisato Kawakami,Takayuki Kii,Hiroki Hara,Ryohei Kawabata,Junji Kawada,Atsushi Takeno,Jin Matsuyama,Shugo Ueda,Yoshihiro Okita,Shunji Endo,Yutaka Kimura,Kazuhiro Yanagihara,Tatsuya Okuno,Yukinori Kurokawa,Toshio Shimokawa,Taroh Satoh
出处
期刊:European Journal of Cancer [Elsevier]
卷期号:154: 307-315 被引量:7
标识
DOI:10.1016/j.ejca.2021.06.035
摘要

There is no standard chemotherapy for esophageal squamous cell carcinoma (ESCC) refractory to first-line fluoropyrimidine- and platinum-based chemotherapy. We therefore performed a randomized, selection-design phase II trial to compare docetaxel (DTX) and paclitaxel (PTX) in this setting.Eligible patients were randomly assigned to receive either DTX (70 mg/m2 on day 1 of each 21-day cycle) or PTX (100 mg/m2 on days 1, 8, 15, 22, 29 and 36 of each 49-day cycle). The primary end-point was overall survival (OS), and secondary end-points included progression-free survival (PFS), time to treatment failure (TTF), response rate (RR) and safety.Seventy-eight eligible patients (N = 39 in each group) were included for efficacy analysis. OS was significantly longer in the PTX group than in the DTX group (median, 8.8 versus 7.3 months; hazard ratio [HR], 0.62; P = 0.047). A significant benefit of PTX over DTX was also apparent in PFS (median, 4.4 versus 2.1 months; HR, 0.49; P = 0.002) and TTF (median, 3.8 versus 2.1 months; HR, 0.45; P < 0.001). RR (25.6% versus 7.7%, P = 0.065) were higher in the PTX group than in the DTX group. Compared to the PTX group, neutropenia (28% versus 80%) and leukopenia (28% versus 76%) of grade ≥3 as well as febrile neutropenia (0% vs. 46%, P < 0.0001) occurred more frequently in the DTX group.PTX showed a significantly better efficacy as well as a more manageable toxicity compared with DTX.UMIN000007940.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
卫卫完成签到 ,获得积分10
1秒前
糖果呖咕呖咕完成签到,获得积分10
1秒前
khurram完成签到,获得积分10
1秒前
默默曼冬完成签到,获得积分10
1秒前
Jasin完成签到,获得积分10
2秒前
2秒前
前程似锦完成签到 ,获得积分10
3秒前
Abi完成签到,获得积分10
3秒前
栖于霞蔚发布了新的文献求助10
3秒前
伤心猪大肠完成签到,获得积分10
4秒前
yzlsci完成签到,获得积分0
4秒前
彭于晏应助潇潇采纳,获得10
4秒前
黑色奢华完成签到,获得积分20
4秒前
5秒前
6秒前
虾条完成签到 ,获得积分10
6秒前
wang完成签到,获得积分10
6秒前
XinEr完成签到 ,获得积分10
6秒前
huahua完成签到,获得积分10
8秒前
张庭豪完成签到,获得积分10
8秒前
棵虫完成签到,获得积分10
8秒前
妙奇完成签到,获得积分10
10秒前
11秒前
lihn完成签到,获得积分10
12秒前
emxzemxz完成签到 ,获得积分10
12秒前
13秒前
奥斯卡发布了新的文献求助10
13秒前
温暖大米完成签到 ,获得积分10
14秒前
leiiiiiiii完成签到,获得积分10
14秒前
神勇的半莲完成签到,获得积分10
14秒前
zz发布了新的文献求助10
15秒前
cannon8发布了新的文献求助10
17秒前
迈克老狼完成签到 ,获得积分10
17秒前
杨帆完成签到,获得积分10
17秒前
充电宝应助小李采纳,获得10
18秒前
20秒前
20秒前
坟里唱情歌完成签到 ,获得积分10
22秒前
RSHL完成签到 ,获得积分10
23秒前
wanghuu发布了新的文献求助10
24秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3081634
求助须知:如何正确求助?哪些是违规求助? 2734500
关于积分的说明 7533221
捐赠科研通 2384096
什么是DOI,文献DOI怎么找? 1264167
科研通“疑难数据库(出版商)”最低求助积分说明 612567
版权声明 597584